Prostate Cancer: HRR Testing Defines Talazoparib Use

The indication depends on disease state and tumor genotype

Talazoparib, a poly(ADP-ribose) polymerase inhibitor, is approved in combination with the androgen receptor inhibitor enzalutamide for adults whose metastatic castration-resistant prostate cancer carries a homologous-recombination-repair, or HRR, gene mutation. Patient selection must use an FDA-approved companion diagnostic.

That wording creates two separate eligibility gates. The cancer must be metastatic and castration resistant, meaning it has progressed despite castrate testosterone levels. It must also test positive for a qualifying HRR alteration covered by an authorized test. A clinical impression of defective DNA repair, family history alone or an unvalidated laboratory result does not fulfill the companion-diagnostic requirement.

The distinction matters because “androgen pathway modulation-naive,” “androgen receptor pathway inhibitor-naive” and “metastatic hormone-sensitive” are not interchangeable with metastatic castration-resistant disease. A patient whose metastatic cancer remains sensitive to androgen deprivation does not fall within the verified FDA indication solely because an HRR mutation is present. Treatment history may help establish whether a patient resembles the trial population, but it does not replace confirmation of the labeled disease state and molecular finding.

The source supplied for this brief describes an FDA decision dated October 26, 2026. That future-dated decision cannot be independently evaluated from the supporting materials available here. The established FDA record is the 2023 approval for HRR gene-mutated metastatic castration-resistant prostate cancer; any later expansion into metastatic castration-sensitive disease would require its own final approval notice and prescribing information.

What the pivotal trial showed

The established approval was supported by TALAPRO-2, a randomized, double-blind, placebo-controlled phase 3 trial. The HRR-deficient efficacy cohort included 399 patients with metastatic castration-resistant prostate cancer. Participants received talazoparib plus enzalutamide or placebo plus enzalutamide, with radiographic progression-free survival assessed by blinded independent central review as the major efficacy outcome.

The combination reduced the hazard of radiographic progression or death by 55% relative to enzalutamide alone. Median radiographic progression-free survival had not been reached in the combination group at the reported analysis, compared with 13.8 months in the control group. Overall survival data were immature, so the progression result should not be interpreted as proof of longer survival.

The study enrolled patients starting systemic treatment for metastatic castration-resistant disease. Prior treatment in earlier, castration-sensitive settings was permitted under protocol-defined conditions, but previous therapy after development of castration resistance was restricted. This context is important when applying the efficacy estimate to patients with more heavily pretreated disease.

Treatment-related toxicity also affects the benefit-risk assessment. Bone marrow suppression was prominent with talazoparib. The FDA summary reported anemia in 66% of patients receiving the combination, including grade 3 or 4 anemia in 43%; corresponding severe neutropenia and thrombocytopenia were also observed. These findings support the label’s requirements for blood-count monitoring, dose interruption or modification when indicated, and assessment of competing causes of cytopenia.

Why an authorized HRR test is not optional

PARP inhibition exploits impaired repair of DNA double-strand breaks. Tumors with pathogenic alterations in genes involved in homologous recombination may therefore be more vulnerable, although treatment effects are not necessarily uniform across every HRR gene. BRCA1 and BRCA2 alterations have generally provided the clearest biological and clinical signal within this drug class, while estimates for less common genes are limited by small subgroups.

An FDA-approved companion diagnostic connects the biomarker used for patient selection to the drug’s reviewed evidence. The test’s labeling defines acceptable specimen types, genes, alteration classes and interpretation rules. This is more specific than ordering any broad next-generation sequencing panel and treating every reported variant as actionable.

Testing may use tumor tissue or circulating tumor DNA when an authorized assay and specimen type apply. Each approach can fail or produce an indeterminate result. Older tissue may contain too little tumor, while plasma testing can miss alterations when circulating tumor DNA is scarce. A negative liquid-biopsy result may therefore justify tissue testing when feasible, but clinicians should follow the relevant diagnostic and drug labels rather than assume the assays are interchangeable.

Variant interpretation is equally important. A pathogenic or likely pathogenic qualifying alteration is different from a variant of uncertain significance. The latter does not establish HRR-deficient disease and should not be used by itself to select talazoparib plus enzalutamide. Germline testing may have implications for relatives, but a germline result and a tumor companion-diagnostic result answer overlapping rather than identical questions.

Practical boundaries of the evidence

For an adult with metastatic castration-resistant prostate cancer, the evidence supports checking whether validated HRR testing has been completed before choosing the combination. Castration should continue through medical androgen deprivation or prior bilateral orchiectomy, consistent with the disease setting evaluated and the prescribing framework.

For metastatic hormone-sensitive or castration-sensitive prostate cancer, the evidence boundary is different. TALAPRO-3 is evaluating talazoparib plus enzalutamide in men with HRR-altered metastatic castration-sensitive disease, but a trial registration is not a regulatory authorization and does not establish benefit. Final results, adverse-event data and an FDA decision would be needed before describing that population as covered by a new indication.

Policy and operational consequences extend beyond the prescription. Health systems need pathways for timely tissue retrieval, reflex molecular testing, plasma testing when appropriate, genetics referral and resolution of uncertain or discordant findings. Payers and laboratories also need to distinguish an FDA-approved companion diagnostic from broader genomic profiling that may be clinically informative but does not necessarily satisfy the label.

Uncertainties that remain

The pivotal comparison was randomized and blinded, supporting a causal interpretation for radiographic progression-free survival in the studied population. However, overall survival was immature at the approval analysis, follow-up for late toxicities was limited, and uncommon HRR-gene subgroups were too small for equally precise estimates.

Generalizability is also constrained by trial eligibility and treatment setting. Patients with substantial marrow compromise, extensive prior treatment or comorbidities that would have excluded them from the trial may experience a different balance of benefit and harm. Pfizer sponsored the development program, making independent replication and mature follow-up particularly valuable.

The supplied future-dated regulatory premise is another limitation. Without a final, indication-specific FDA notice and label supporting a 2026 expansion, clinicians and policymakers should not infer that metastatic androgen pathway modulation-naive or hormone-sensitive disease is already included.

Questions clinicians ask

Does every patient with metastatic prostate cancer qualify?

No. The verified indication requires metastatic castration-resistant prostate cancer plus a qualifying HRR gene mutation identified with an FDA-approved companion diagnostic. Metastatic hormone-sensitive disease, prior androgen-pathway treatment status or family history alone does not satisfy both requirements.

Can a variant of uncertain significance support treatment selection?

A variant of uncertain significance is not established as pathogenic and should not be treated as a qualifying HRR mutation by default. Eligibility should be based on the authorized test’s report, its companion-diagnostic labeling and the talazoparib prescribing information.

What if plasma testing is negative?

A negative circulating-tumor-DNA result may be uninformative when little tumor DNA is present in plasma. If suspicion remains and adequate material can be obtained, tissue testing with an appropriately authorized assay may clarify status; assay-specific labeling should guide how negative and indeterminate results are handled.

Is the combination approved for metastatic hormone-sensitive disease?

Not on the basis of the independently verifiable FDA materials summarized here. TALAPRO-3 is studying that setting, but trial enrollment or registration does not equal approval; a final FDA notice and updated prescribing information would be required to confirm any expanded indication.

References

1. Oncology (Cancer)/Hematologic Malignancies Approval Notifications — US Food and Drug Administration, 2026
2. Talazoparib With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer — ClinicalTrials.gov, 2024
3. Talazoparib With Enzalutamide in Men With DDR Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer — ClinicalTrials.gov, 2025